REDUCE LAP-HF RANDOMIZED TRIAL I (NCT02600234)

🧪 Interventions in This Study

• Inter-Atrial Shunt Device (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (21 Sites)

• University of Arizona College of Medicine — Tucson, Arizona
• Yale University — New Haven, Connecticut
• Northwestern University — Chicago, Illinois
• Evanston Northshore Healthcare — Evanston, Illinois
• Cardiovascular Institute of the South — Houma, Louisiana
• Ochsner Medical Center — New Orleans, Louisiana
• Massachusetts General Hospital — Boston, Massachusetts
• University of Michigan Health System — Ann Arbor, Michigan
• Mayo Clinic — Rochester, Minnesota
• Columbia University Medical Center/NewYork Presbyterian Hospital — New York, New York
• Mt. Sinai Hospital — New York, New York
• New York University — New York, New York
• Wake Forest — Winston-Salem, North Carolina
• Ohio Health — Columbus, Ohio
• Ohio State University College of Medicine — Columbus, Ohio
• University of Pennsylvania — Philadelphia, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina
• The Alfred Hospital — Melbourne,
• OLVZ Aalst — Aalst,
• UMC Groningen — Groningen,
• Golden Jubilee Hospital — Glasgow,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Heart Failure

• REDUCE LAP-HFREF TRIAL — New York, New York
• Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
• DASH Diet in Heart Failure Outpatients — Sacramento, California
• Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients — Huntsville, Alabama
• LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Birmingham, Alabama
• A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Alexander City, Alabama

Explore by condition: All Heart Failure clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.